Drug intelligence / Profile preview

WPV02

Development stage: Preclinical
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules

Overview

WPV02 is a preclinical-stage small molecule antiviral candidate being developed by Westlake Pharmaceuticals for the treatment of coronavirus infections. The drug is part of the company's infectious disease pipeline, which focuses on developing therapies for viral pathogens. While the specific molecular target of WPV02 has not been publicly disclosed, it is being optimized for potency and safety in preclinical models to address the ongoing need for diverse antiviral options against SARS-CoV-2 and related viruses.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)

Beyond the preview

Go deeper on WPV02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPV02.

Explore the full profile